BETHLEHEM, Pa. — The Food and Drug Administration has approved a new Daiichi Sankyo manufacturing center that the company said would strengthen its domestic and global supply chain.
The Japan-based drug maker said it received FDA approval to package products at the plant, in Bethlehem, Pa. The company said it would be the first noncontracted U.S. manufacturing operation. The plant employs 39 people, and there are plans to hire more.
The 140,000-sq.-ft. plant will package some of Daiichi Sankyo's cardiovascular and metabolic drugs, including treatments for high blood pressure, heart disease, diabetes and lipid disorders.